Anti-METTL3 Rabbit Monoclonal Antibody [KD Validated] for WB, IP, IF/ICC, IHC-P, ChIP, ELISA - Q86U44

Core Product Specifications and Parameters

Biological Background: METTL3 Function and Localization

• METTL3 (N(6)-adenosine-methyltransferase catalytic subunit) is a 64 kDa protein that localizes to nuclear speckles and the cytoplasm. It forms a heterodimeric complex with METTL14 that constitutes the catalytic core for depositing m6A modifications on RNA.
  Related references:
  PMID:27281194
  PMID:27373337
  PMID:27627798
• METTL3 deposits m6A at the consensus sequence 5′-[AG]GAC-3′ on mRNA, regulating transcript stability, processing, translation efficiency, and editing.
  Related references:
  PMID:22575960
  PMID:24284625
  PMID:25719671
• The m6A mark promotes mRNA destabilization and degradation once mRNAs are released into the nucleoplasm, enabling dynamic control of gene expression.
  Related references:
  PMID:28637692
• In embryonic stem cells, m6A methylation of pluripotency-associated transcripts by METTL3 drives their decay, thereby facilitating exit from the naïve state and differentiation.
• METTL3 contributes to circadian clock regulation by accelerating nuclear processing of clock gene mRNAs and modulating hepatic lipid metabolism.
  Related references:
  PMID:30428350
• Upon UV‑induced DNA damage, METTL3 is rapidly recruited to damage sites where it catalyzes m6A on poly(A) transcripts, promoting the recruitment of DNA polymerase κ (POLK).
  Related references:
  PMID:28297716
• In the cytoplasm, METTL3 interacts with translation initiation factors to enhance mRNA translation independently of its methyltransferase activity; this function is associated with cancer cell proliferation.
  Related references:
  PMID:27117702
• During SARS‑CoV‑2 infection, METTL3 adds m6A modifications to viral RNA, reducing RIG‑I binding and thereby dampening innate immune sensing.
  Related references:
  PMID:33961823

Experimental Guidance and Technical Tips

• The immunogen corresponds to the N‑terminal region (amino acids 1–156) of human METTL3. When using this antibody, consider that it may recognize epitopes within this fragment; validate binding to full‑length METTL3 and potential isoforms in your sample system.
• For Western blot, the predicted molecular weight is ~64 kDa. Optimize gel percentage (e.g., 10% SDS‑PAGE) and transfer conditions for mid‑sized proteins. Use appropriate positive and negative controls.
• The antibody’s reported suitability for ChIP suggests it can immunoprecipitate METTL3–RNA or chromatin complexes; fine‑tune cross‑linking, sonication, and wash stringency for your specific protocol.
• In immunofluorescence (IF/ICC) and immunohistochemistry (IHC‑P), fixation and permeabilization conditions should be optimized to preserve the epitope while allowing antibody access.
• Multiple applications are listed; however, each laboratory should establish and optimize the antibody performance under its own experimental conditions.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio is your one‑stop IVD raw‑material sourcing partner, delivering validated antibody pairs, monoclonal/polyclonal antibodies, and bulk ancillary reagents for epitranscriptomic and cancer research. From initial assay design to clinical validation, we support your development of reliable diagnostic tools targeting RNA modification pathways.